Clinical Trial Update: Dose Ranging Study of ALX-0171 in Infants Hospitalized for Respiratory Syncytial Virus Lower Respiratory Tract Infection [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging study of ALX-0171 in infants hospitalized with respiratory syncytial virus lower respiratory tract infection has completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Lower Respiratory Tract Infection

Drugs mentioned

• ALX-0171

Snippet

Sponsor: Ablynx, a Sanofi company | Conditions: Respiratory Syncytial Virus Lower Respiratory Tract Infection | Phase 2 | Status: COMPLETED | Results posted: 2019-10-18